AUG 25, 2020 3:39 PM PDT

Synthetic Cannabinoid Drug to Enter Human Trials

WRITTEN BY: Annie Lennon

In recent months, interest has been growing in the potential for cannabinoids- the compounds found in cannabis- to treat COVID-19. And now, the US Food and Drug Administration has approved a synthetic cannabinoid drug, known as ARDS-003, for Phase I clinical trials. 

ARDS-003 was created by researchers at Tetra Bio-Pharma, a pharmaceutical company specializing in cannabinoid-derived drug discovery and development. In particular, the company created the drug to tackle acute respiratory distress syndrome (ARDS), common in severe cases of COVID-19. 

“We have extensive preclinical evidence that the active pharmaceutical ingredient (API) in ARDS-003 has a profound effect in inhibiting the factors that lead to excessive immune system activation,” says Dr. Guy Chamberland, and Chief of Regulatory Officer at Tetra Bio-Pharma.

A synthetic compound, ARDS-003 does not come from the cannabis plant. It does ,however, work on the same endocannabinoid system similarly to natural cannabinoids. In particular, it binds to CB2 receptors, responsible for modulating inflammation and cytokine activity.

By targeting the CB2 receptor, the drug is able to impact many pro-inflammatory signaling pathways. As such, it disables the excessive release of immune cells, which can cause ARDS. Unlike cannabis, the drug does not activate the CB1 receptor, known to make people feel high. 

While many believe that vaccines are the best way to solve the pandemic crisis, Chamerberland says that it will take time to know whether protection from them is long-lasting, and how they work in different age-groups, ethnicities, and people with underlying health conditions. 

More than this, even it were to work, he notes that it will be difficult to dose everyone with a vaccine quickly, and many may choose not to take them. Thus, the development of drugs that can tackle the virus head-on are just as necessary as a public health safety measure. 

Phase I trials for ARDS-003, are currently scheduled to begin enrolling patients in December 2020 under randomized, double-blind, placebo-controlled conditions. This trial will test the drug on healthy individuals to confirm its safety. 

Once confirmed, the researchers may then begin to test the drug’s safety in those with COVID-19, likely in the second quarter of 2021. Should all go to plan, tests looking at whether the drug can treat ARDS will begin at the end of 2021. 

 

Sources: ForbesBioSpace

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 10, 2020
Cannabis Sciences
Should We Be Concerned About Cannabis Poisoning in Minors?
JUN 10, 2020
Should We Be Concerned About Cannabis Poisoning in Minors?
The Canadian federal government began legalizing aspects of recreational marijuana use in October 2018, so researchers a ...
JUN 23, 2020
Health & Medicine
New Evidence Medical Cannabis Can Lead to Decreased Opioid Use in Chronic Pain
JUN 23, 2020
New Evidence Medical Cannabis Can Lead to Decreased Opioid Use in Chronic Pain
For people with long term ongoing pain, medical cannabis is a valid option that could pave the way to reduced use of opi ...
JUL 07, 2020
Cannabis Sciences
Why Cannabis Makes Everything Seem Interesting
JUL 07, 2020
Why Cannabis Makes Everything Seem Interesting
Experiencing novelty- or new things- is something most people look forward to. Whether it's traveling to new places, ...
AUG 11, 2020
Cannabis Sciences
High THC Cannabis Linked to Anxiety
AUG 11, 2020
High THC Cannabis Linked to Anxiety
Researchers have found that people who use strains of cannabis high in tetrahydrocannabinol (THC), the psychoactive comp ...
AUG 27, 2020
Health & Medicine
Study Confirms E-cigarettes and Marijuana Not to Blame for Vaping-Related Lung Injuries
AUG 27, 2020
Study Confirms E-cigarettes and Marijuana Not to Blame for Vaping-Related Lung Injuries
A Yale School of Public Health report published August 25 2020 in the journal Addiction confirms that it was neither e-c ...
SEP 15, 2020
Cannabis Sciences
Cannabis Blood Tests Unreliable for Testing Intoxication
SEP 15, 2020
Cannabis Blood Tests Unreliable for Testing Intoxication
Researchers from the University of British Columbia have found that tetrahydrocannabinol (THC), the psychoactive compoun ...
Loading Comments...